{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:33:15Z","timestamp":1783089195470,"version":"3.54.6"},"reference-count":128,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cholinergic antagonists interfere with synaptic transmission in the central nervous system and are involved in pathological processes in patients with neurocognitive disorders (NCD), such as behavioral and psychological symptoms of dementia (BPSD). In this commentary, we will briefly review the current knowledge on the impact of cholinergic burden on BPSD in persons with NCD, including the main pathophysiological mechanisms. Given the lack of clear consensus regarding symptomatic management of BPSD, special attention must be paid to this preventable, iatrogenic condition in patients with NCD, and de-prescription of cholinergic antagonists should be considered in patients with BPSD.<\/jats:p>","DOI":"10.3390\/ijms24086921","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T03:49:29Z","timestamp":1681098569000},"page":"6921","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cholinergic Antagonists and Behavioral Disturbances in Neurodegenerative Diseases"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4741-1934","authenticated-orcid":false,"given":"Rachid","family":"Mahmoudi","sequence":"first","affiliation":[{"name":"Department of Geriatric and Internal Medicine, Reims University Hospitals, Maison Blanche Hospital, 51092 Reims, France"},{"name":"UR 3797 Vieillissement, Fragilit\u00e9 (VieFra), Faculty of Medicine, University of Reims Champagne-Ardenne, 51687 Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Luc","family":"Novella","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Internal Medicine, Reims University Hospitals, Maison Blanche Hospital, 51092 Reims, France"},{"name":"UR 3797 Vieillissement, Fragilit\u00e9 (VieFra), Faculty of Medicine, University of Reims Champagne-Ardenne, 51687 Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Laurent-Badr","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Internal Medicine, Reims University Hospitals, Maison Blanche Hospital, 51092 Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Boulahrouz","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Internal Medicine, Reims University Hospitals, Maison Blanche Hospital, 51092 Reims, France"},{"name":"UR 3797 Vieillissement, Fragilit\u00e9 (VieFra), Faculty of Medicine, University of Reims Champagne-Ardenne, 51687 Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Internal Medicine, Reims University Hospitals, Maison Blanche Hospital, 51092 Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-3295","authenticated-orcid":false,"given":"Isabella","family":"Morrone","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Internal Medicine, Reims University Hospitals, Maison Blanche Hospital, 51092 Reims, France"},{"name":"Cognition Health and Society Laboratory (C2S-EA 6291), Faculty of Medicine, University of Reims Champagne-Ardenne, 51687 Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9959-7227","authenticated-orcid":false,"given":"Yacine","family":"Ja\u00efdi","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Internal Medicine, Reims University Hospitals, Maison Blanche Hospital, 51092 Reims, France"},{"name":"UR 3797 Vieillissement, Fragilit\u00e9 (VieFra), Faculty of Medicine, University of Reims Champagne-Ardenne, 51687 Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ardp.19652980111","article-title":"Nobel lectures-physiology or medicine 1942\u20131962. Herausgegeben von der Nobel-Stiftung. 840 Seiten. Elsevier Publishing Co, Amsterdam\u2014London\u2014New York 1964. Preis etwa DM 90,\u2014","volume":"298","author":"Auterhoff","year":"1965","journal-title":"Arch. Pharm. Pharm. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer\u2019s disease","volume":"2","author":"Davies","year":"1976","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(77)91780-9","article-title":"Necropsy evidence of central cholinergic deficits in senile dementia","volume":"1","author":"Perry","year":"1977","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/266558a0","article-title":"Selective vulnerability of neurones in organic dementia","volume":"266","author":"Spillane","year":"1977","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(77)92114-6","article-title":"Neocortical Cholinergic Neurons in Elderly People","volume":"309","author":"White","year":"1977","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00697388","article-title":"Loss of neurons in the nucleus basalis of Meynert in Alzheimer\u2019s disease, paralysis agitans and Korsakoff\u2019s Disease","volume":"61","author":"Arendt","year":"1983","journal-title":"Acta Neuropathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.7058341","article-title":"Alzheimer\u2019s disease and senile dementia: Loss of neurons in the basal forebrain","volume":"215","author":"Whitehouse","year":"1982","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/archneur.1974.00490320001001","article-title":"Human memory and the cholinergic system. A relationship to aging?","volume":"30","author":"Drachman","year":"1974","journal-title":"Arch. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.bcp.2007.05.023","article-title":"Heterogeneity and complexity of native brain nicotinic receptors","volume":"74","author":"Gotti","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.pharmthera.2009.03.009","article-title":"A cog in cognition: How the \u03b17 nicotinic acetylcholine receptor is geared towards improving cognitive deficits","volume":"122","author":"Leiser","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0163-7258(01)00161-9","article-title":"Neuronal nicotinic acetylcholine receptor subunit knockout mice: Physiological and behavioral phenotypes and possible clinical implications","volume":"92","author":"Picciotto","year":"2001","journal-title":"Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0079-6123(03)45011-5","article-title":"Activity, modulation and role of basal forebrain cholinergic neurons innervating the cerebral cortex","volume":"145","author":"Jones","year":"2004","journal-title":"Prog. Brain Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"B\u00fcrli, T., Baer, K., Ewers, H., Sidler, C., Fuhrer, C., and Fritschy, J.-M. (2010). Single Particle Tracking of \u03b17 Nicotinic AChR in Hippocampal Neurons Reveals Regulated Confinement at Glutamatergic and GABAergic Perisynaptic Sites. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0011507"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0079-6123(03)45003-6","article-title":"Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus","volume":"145","author":"Volpicelli","year":"2004","journal-title":"Prog. Brain Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cmet.2006.04.009","article-title":"A critical role for \u03b2 cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo","volume":"3","author":"Gautam","year":"2006","journal-title":"Cell Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrd2379","article-title":"Muscarinic acetylcholine receptors: Mutant mice provide new insights for drug development","volume":"6","author":"Wess","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"13541","DOI":"10.1073\/pnas.93.24.13541","article-title":"Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease","volume":"93","author":"Levey","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","first-page":"11","article-title":"Anticholinergic effects of medication in elderly patients","volume":"62","author":"Tune","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1176\/ajp.149.10.1393","article-title":"Anticholinergic effects of drugs commonly prescribed for the elderly: Potential means for assessing risk of delirium","volume":"149","author":"Tune","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2174\/138920011796504518","article-title":"Paying attention to pharmacokinetic and pharmacodynamic mechanisms to progress in the area of anticholinergic use in geriatric patients","volume":"12","year":"2011","journal-title":"Curr. Drug Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1586\/ecp.10.34","article-title":"Association between prescribing of antimuscarinic drugs and antimuscarinic adverse effects in older people","volume":"3","author":"Bostock","year":"2010","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lavrador, M., Cabral, A.C., Ver\u00edssimo, M.T., Fernandez-Llimos, F., Figueiredo, I.V., and Castel-Branco, M.M. (2023). A Universal Pharmacological-Based List of Drugs with Anticholinergic Activity. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15010230"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1476-5381.1980.tb14570.x","article-title":"The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors","volume":"68","author":"Golds","year":"1980","journal-title":"Br. J. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/archpsyc.1980.01780160063007","article-title":"Serum Levels of Anticholinergic Drugs in Treatment of Acute Extrapyramidal Side Effects","volume":"37","author":"Tune","year":"1980","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0304-3940(94)90064-7","article-title":"Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia","volume":"177","author":"Tohgi","year":"1994","journal-title":"Neurosci. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/BF01271206","article-title":"Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia","volume":"103","author":"Tohgi","year":"1996","journal-title":"J. Neural Transm. (Vienna)"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s40266-018-0549-z","article-title":"Anticholinergic Drug Burden Tools\/Scales and Adverse Outcomes in Different Clinical Settings: A Systematic Review of Reviews","volume":"35","author":"Welsh","year":"2018","journal-title":"Drugs Aging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00228-020-02994-x","article-title":"Quality of anticholinergic burden scales and their impact on clinical outcomes: A systematic review","volume":"77","author":"Lisibach","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Salahudeen, M.S., Duffull, S.B., and Nishtala, P.S. (2015). Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: A systematic review. BMC Geriatr., 15.","DOI":"10.1186\/s12877-015-0029-9"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10072-011-0618-0","article-title":"Memantine effects on behaviour in moderately severe to severe Alzheimer\u2019s disease: A post-marketing surveillance study","volume":"33","author":"Clerici","year":"2012","journal-title":"Neurol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40266-012-0044-x","article-title":"Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: Comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: Results from the REPOSI study","volume":"30","author":"Pasina","year":"2013","journal-title":"Drug Aging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jamda.2016.07.012","article-title":"Anticholinergic Medication Burden and 5-Year Risk of Hospitalization and Death in Nursing Home Elderly Residents With Coronary Artery Disease","volume":"17","author":"Vetrano","year":"2016","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/jgs.13054","article-title":"Multiple Anticholinergic Medication Use and Risk of Hospital Admission for Confusion or Dementia","volume":"62","author":"Pratt","year":"2014","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/psyg.12291","article-title":"Risk of hospitalization associated with anticholinergic medication for patients with dementia","volume":"18","author":"Watanabe","year":"2018","journal-title":"Psychogeriatrics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3233\/JAD-180353","article-title":"Anticholinergic Burden and Risk of Stroke and Death in People with Different Types of Dementia","volume":"65","author":"Tan","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"ref_37","first-page":"705","article-title":"Anticholinergic burden and 1-year mortality among older patients discharged from acute care hospital","volume":"18","author":"Lattanzio","year":"2018","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JAD-170265","article-title":"Potentially Inappropriate Medication, Anticholinergic Burden, and Mortality in People Attending Memory Clinics","volume":"60","author":"Cross","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"ref_39","first-page":"404","article-title":"Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer\u2019s type","volume":"10","author":"Pinto","year":"2011","journal-title":"Ageing Res. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S351","DOI":"10.1002\/mds.21683","article-title":"Cholinergic and other neurotransmitter mechanisms in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies","volume":"22","author":"Francis","year":"2007","journal-title":"Mov. Diord."},{"key":"ref_41","first-page":"S64","article-title":"The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer\u2019s disease","volume":"6","author":"Cummings","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/gps.1858","article-title":"Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: The Cache County Study","volume":"23","author":"Steinberg","year":"2008","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1017\/S1041610297003943","article-title":"Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment","volume":"8","author":"Finkel","year":"1996","journal-title":"Int. Psychogeriatr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1474-4422(05)70219-2","article-title":"Behavioural changes and psychological symptoms in dementia disorders","volume":"4","author":"McKeith","year":"2005","journal-title":"Lancet Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/gerona\/58.6.M548","article-title":"Presence of behavioral and psychological symptoms predicts nursing home placement in community-dwelling elders with cognitive impairment in univariate but not multivariate analysis","volume":"58","author":"Chan","year":"2003","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.arr.2014.03.003","article-title":"Multivariate models of subjective caregiver burden in dementia: A systematic review","volume":"15","author":"Bakker","year":"2014","journal-title":"Ageing Res. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jagp.2013.01.049","article-title":"Neuropsychiatric Symptoms as Risk Factors for Progression From CIND to Dementia: The Cache County Study","volume":"21","author":"Peters","year":"2013","journal-title":"Am. J. Geritar. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S1041610218000534","article-title":"Management of behavioral and psychological symptoms in people with Alzheimer\u2019s disease: An international Delphi consensus","volume":"31","author":"Kales","year":"2019","journal-title":"Intl. Psychogeriatr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","article-title":"Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease","volume":"12","author":"Hardy","year":"1991","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0006-8993(89)91396-6","article-title":"Accumulation of abnormally phosphorylated \u03c4 precedes the formation of neurofibrillary tangles in Alzheimer\u2019s disease","volume":"477","author":"Bancher","year":"1989","journal-title":"Brain Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/gps.5030","article-title":"Using electronic health records to estimate the prevalence of agitation in Alzheimer disease\/dementia","volume":"34","author":"Halpern","year":"2019","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jad.2015.09.069","article-title":"The prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease: Systematic review and meta-analysis","volume":"190","author":"Zhao","year":"2016","journal-title":"J. Affect. Disord."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jamapsychiatry.2016.0004","article-title":"Trajectories of Depressive Symptoms in Older Adults and Risk of Dementia","volume":"73","author":"Kaup","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neurobiolaging.2019.10.008","article-title":"Apathy and anxiety are early markers of Alzheimer\u2019s disease","volume":"85","author":"Johansson","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1192\/bjp.2019.195","article-title":"The individual course of neuropsychiatric symptoms in people with Alzheimer\u2019s and Lewy body dementia: 12-year longitudinal cohort study","volume":"216","author":"Giil","year":"2020","journal-title":"Br. J. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2217\/1745509X.4.3.311","article-title":"Impact of anticholinergics on the aging brain: A review and practical application","volume":"4","author":"Boustani","year":"2008","journal-title":"Aging Health"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13195-017-0284-4","article-title":"Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders","volume":"9","author":"Dauphinot","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.clpt.6100435","article-title":"Drugs with Anticholinergic Properties as a Risk Factor for Psychosis in Patients Affected by Alzheimer\u2019s Disease","volume":"84","author":"Cancelli","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000321591","article-title":"Influence of anticholinergic activity in serum on clinical symptoms of Alzheimer\u2019s disease","volume":"63","author":"Hori","year":"2011","journal-title":"Neuropsychobiology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/archpsyc.1987.01800170032006","article-title":"Anticholinergic Sensitivity in Patients With Dementia of the Alzheimer Type and Age-Matched Controls: A Dose-Response Study","volume":"44","author":"Sunderland","year":"1987","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jagp.2017.08.005","article-title":"Reduction of the Anticholinergic Burden Makes It Possible to Decrease Behavioral and Psychological Symptoms of Dementia","volume":"26","author":"Nonnonhou","year":"2018","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1177\/0091270006292126","article-title":"The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: Associations with serum anticholinergic activity","volume":"46","author":"Carnahan","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jamda.2018.10.015","article-title":"Threshold for a Reduction in Anticholinergic Burden to Decrease Behavioral and Psychological Symptoms of Dementia","volume":"20","author":"Guilloteau","year":"2019","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fphar.2020.00030","article-title":"Are Anticholinergic Medications Associated With Increased Risk of Dementia and Behavioral and Psychological Symptoms of Dementia? A Nationwide 15-Year Follow-Up Cohort Study in Taiwan","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00019442-200504000-00009","article-title":"Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications","volume":"13","author":"Jewart","year":"2005","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.47.4.876","article-title":"Neuropsychiatric aspects of Alzheimer\u2019s disease. The cholinergic hypothesis revisited","volume":"47","author":"Cummings","year":"1996","journal-title":"Neurology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1212\/WNL.55.10.1460","article-title":"Cholinergic deficits contribute to behavioral disturbance in patients with dementia","volume":"55","author":"Minger","year":"2000","journal-title":"Neurology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuropsychologia.2004.06.007","article-title":"Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer\u2019s disease","volume":"43","author":"Chen","year":"2005","journal-title":"Neuropsychologia"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12017-008-8048-8","article-title":"Genetic Variation in the \u03b17 Nicotinic Acetylcholine Receptor is Associated with Delusional Symptoms in Alzheimer\u2019s Disease","volume":"10","author":"Carson","year":"2008","journal-title":"Neuromolecular Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41537-020-0105-9","article-title":"The role of nicotinic cholinergic neurotransmission in delusional thinking","volume":"6","author":"Caton","year":"2020","journal-title":"NPJ Schizophr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.57.5.805","article-title":"Psychosis of Alzheimer\u2019s disease is associated with elevated muscarinic M2 binding in the cortex","volume":"57","author":"Lai","year":"2001","journal-title":"Neurology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0169-328X(92)90194-G","article-title":"Comparison of the concentration of messenger RNA encoding four muscarinic receptor subtypes in control and Alzheimer brains","volume":"16","author":"Wang","year":"1992","journal-title":"Brain Res. Mol. Brain Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00213-008-1124-9","article-title":"Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimer\u2019s disease patients with psychosis","volume":"198","author":"Tsang","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1353-8020(13)70017-8","article-title":"\u03b1-Synucleinopathy phenotypes","volume":"20","author":"McCann","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.archger.2007.03.003","article-title":"Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): Frequency and relationship with disease severity and motor impairment","volume":"46","author":"Borroni","year":"2008","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/121.10.1819","article-title":"Complex visual hallucinations. Clinical and neurobiological insights","volume":"121","author":"Manford","year":"1998","journal-title":"Brain"},{"key":"ref_77","first-page":"5380202","article-title":"Mini Review: Anticholinergic Activity as a Behavioral Pathology of Lewy Body Disease and Proposal of the Concept of \u201cAnticholinergic Spectrum Disorders\u201d","volume":"2016","author":"Hori","year":"2016","journal-title":"Park. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0166-2236(98)01361-7","article-title":"Acetylcholine in mind: A neurotransmitter correlate of consciousness?","volume":"22","author":"Perry","year":"1999","journal-title":"Trends Neurosci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbr.2005.02.019","article-title":"Muscarinic M2 and M4 receptors in anterior cingulate cortex: Relation to neuropsychiatric symptoms in dementia with Lewy bodies","volume":"161","author":"Teaktong","year":"2005","journal-title":"Behav. Brain Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neuroimage.2006.07.026","article-title":"In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson\u2019s disease dementia","volume":"33","author":"Colloby","year":"2006","journal-title":"NeuroImage"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/jnnp.67.2.209","article-title":"Alterations of muscarinic acetylcholine receptor subtypes in diffuse lewy body disease: Relation to Alzheimer\u2019s disease","volume":"67","author":"Shiozaki","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1006\/brcg.1995.1255","article-title":"Acetylcholine and hallucinations: Disease-related compared to drug-induced alterations in human consciousness","volume":"28","author":"Perry","year":"1995","journal-title":"Brain Cogn."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/1531-8249(200012)48:6<868::AID-ANA7>3.0.CO;2-0","article-title":"Delusions associated with elevated muscarinic binding in dementia with Lewy bodies","volume":"48","author":"Ballard","year":"2000","journal-title":"Ann. Neurol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.maturitas.2014.07.001","article-title":"What is frontotemporal dementia?","volume":"79","author":"Kurz","year":"2014","journal-title":"Maturitas"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fneur.2019.00594","article-title":"Psychological and Cognitive Markers of Behavioral Variant Frontotemporal Dementia-A Clinical Neuropsychologist\u2019s View on Diagnostic Criteria and Beyond","volume":"10","author":"Johnen","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_86","first-page":"507","article-title":"Neocortical morphometry and cholinergic neurochemistry in Pick\u2019s disease","volume":"131","author":"Hansen","year":"1988","journal-title":"Am. J. Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0022-510X(80)90205-1","article-title":"Neurochemical observations in a case of Pick\u2019s disease","volume":"48","author":"Yates","year":"1980","journal-title":"J. Neurol. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jalz.2016.10.007","article-title":"The Vascular Impairment of Cognition Classification Consensus Study","volume":"13","author":"Skrobot","year":"2017","journal-title":"Alzheimers Dement."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jagp.2021.12.014","article-title":"Neuropsychiatric Symptoms as Predictor of Poor Clinical Outcome in Patients With Vascular Cognitive Impairment","volume":"30","author":"Sep","year":"2022","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/jscd.2003.5","article-title":"Strategic involvement of cholinergic pathways and executive dysfunction: Does location of white matter signal hyperintensities matter?","volume":"12","author":"Swartz","year":"2003","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1212\/01.WNL.0000055927.22611.EB","article-title":"Cholinergic denervation in a pure multi-infarct state: Observations on CADASIL","volume":"60","author":"Mesulam","year":"2003","journal-title":"Neurology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000072803","article-title":"Decreased Cerebrospinal Fluid Acetylcholinesterase in Patients with Subcortical Ischemic Vascular Dementia","volume":"16","author":"Wallin","year":"2003","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jamda.2019.06.001","article-title":"Interventions to Reduce Anticholinergic Burden in Adults Aged 65 and Older: A Systematic Review","volume":"21","author":"Nakham","year":"2020","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11096-019-00784-9","article-title":"DEFEAT-polypharmacy: Deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities","volume":"41","author":"Ailabouni","year":"2019","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1017\/S1041610220004032","article-title":"Prevalence of psychotropic polypharmacy in nursing home residents with dementia: A meta-analysis","volume":"33","author":"Jester","year":"2021","journal-title":"Int. Psychogeriatr."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2021.1195","article-title":"Prevalence of Central Nervous System\u2013Active Polypharmacy Among Older Adults With Dementia in the US","volume":"325","author":"Maust","year":"2021","journal-title":"JAMA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00702-020-02298-5","article-title":"Current use of anticholinergic medications in a large naturalistic sample of psychiatric patients","volume":"128","author":"Toto","year":"2021","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3389\/fnins.2019.01309","article-title":"Anticholinergic Drugs in Geriatric Psychopharmacology","volume":"13","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","article-title":"The anticholinergic risk scale and anticholinergic adverse effects in older persons","volume":"168","author":"Rudolph","year":"2008","journal-title":"Arch. Inter. Med."},{"key":"ref_100","first-page":"CD015196","article-title":"Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia","volume":"8","author":"Kraia","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/CIA.S4250","article-title":"Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer\u2019s disease: A meta-analysis","volume":"3","author":"Campbell","year":"2008","journal-title":"Clin. Interv. Aging"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000113034","article-title":"Galantamine in frontotemporal dementia and primary progressive aphasia","volume":"25","author":"Kertesz","year":"2008","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/01.JGP.0000231744.69631.33","article-title":"Preliminary findings: Behavioral worsening on donepezil in patients with frontotemporal dementia","volume":"15","author":"Mendez","year":"2007","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000200013","article-title":"Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer\u2019s disease","volume":"27","author":"Grossberg","year":"2009","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Chen, R., Chan, P.T., Chu, H., Lin, Y.C., Chang, P.C., Chen, C.Y., and Chou, K.R. (2017). Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183586"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1345\/aph.1K372","article-title":"Efficacy of memantine on behavioral and psychological symptoms related to dementia: A systematic meta-analysis","volume":"42","author":"Maidment","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1017\/neu.2015.61","article-title":"The effect of memantine on sleep architecture and psychiatric symptoms in patients with Alzheimer\u2019s disease","volume":"28","author":"Ishikawa","year":"2016","journal-title":"Acta Neuropsychiatr."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.tips.2019.10.007","article-title":"Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders","volume":"40","author":"Moran","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/bs.apha.2019.12.003","article-title":"Chapter Ten\u2014M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer\u2019s disease?","volume":"88","author":"Scarpa","year":"2020","journal-title":"Adv. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1523\/JNEUROSCI.11-10-03218.1991","article-title":"Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies","volume":"11","author":"Levey","year":"1991","journal-title":"J. Neurosci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ajpath.2011.04.041","article-title":"Loss of muscarinic M1 receptor exacerbates Alzheimer\u2019s disease-like pathology and cognitive decline","volume":"179","author":"Medeiros","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_113","first-page":"S16","article-title":"The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease","volume":"11","author":"Bodick","year":"1997","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1017\/S1461145712000752","article-title":"The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction","volume":"16","author":"Nathan","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"14271","DOI":"10.1523\/JNEUROSCI.3930-09.2009","article-title":"A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning","volume":"29","author":"Shirey","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1021\/acs.jmedchem.6b00544","article-title":"Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects","volume":"59","author":"Davoren","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0024-3205(97)00044-1","article-title":"Muscarinic acetylcholine receptor subtype, m2: Diverse functional implications of differential synaptic localization","volume":"60","author":"Rouse","year":"1997","journal-title":"Life Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.2174\/138161205774370762","article-title":"Muscarinic receptor agonists and antagonists in the treatment of Alzheimer\u2019s disease","volume":"11","author":"Clader","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/jphp.12919","article-title":"Muscarinic and nicotinic acetylcholine receptor agonists: Current scenario in Alzheimer\u2019s disease therapy","volume":"70","author":"Verma","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"9440","DOI":"10.1073\/pnas.0914801107","article-title":"The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation\/arrestin-dependent manner","volume":"107","author":"Poulin","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.neuroscience.2018.01.063","article-title":"Regulation of Phosphorylation of AMPA Glutamate Receptors by Muscarinic M4 Receptors in the Striatum In vivo","volume":"375","author":"Mao","year":"2018","journal-title":"Neuroscience"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1096\/fj.04-1575fje","article-title":"M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: Relevance to the pathophysiology and treatment of related CNS pathologies","volume":"18","author":"Tzavara","year":"2004","journal-title":"FASEB J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1073\/pnas.0800567105","article-title":"Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia","volume":"105","author":"Chan","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"8772","DOI":"10.1523\/JNEUROSCI.0901-14.2014","article-title":"Striatal Cholinergic Neurotransmission Requires VGLUT3","volume":"34","author":"Nelson","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nn.2984","article-title":"GABAergic circuits mediate the reinforcement-related signals of striatal cholinergic interneurons","volume":"15","author":"English","year":"2011","journal-title":"Nat. Neurosci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0091-3057(01)00644-X","article-title":"Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies","volume":"70","author":"Court","year":"2001","journal-title":"Pharmacol. Biochem Behavr."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00213-003-1668-7","article-title":"AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors","volume":"172","author":"Selbach","year":"2004","journal-title":"Psychopharmacology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1124\/jpet.106.118976","article-title":"The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents","volume":"321","author":"Boess","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/8\/6921\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:12:19Z","timestamp":1760123539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/8\/6921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":128,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24086921"],"URL":"https:\/\/doi.org\/10.3390\/ijms24086921","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]}}}